Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
15.33
-0.02 (-0.13%)
May 29, 2026, 4:00 PM EDT - Market closed
Aurinia Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 298.3 | 283.06 | 235.13 | 175.51 | 134.03 | 45.61 | |
Revenue Growth (YoY) | 20.62% | 20.38% | 33.97% | 30.95% | 193.89% | -9.01% |
Cost of Revenue | 30.6 | 32.67 | 28.25 | 14.15 | 5.66 | 1.09 |
Gross Profit | 267.7 | 250.39 | 206.89 | 161.37 | 128.37 | 44.51 |
Selling, General & Admin | 103.48 | 101.79 | 172.03 | 195.04 | 196.37 | 173.54 |
Research & Development | 34.23 | 32.51 | 20.79 | 49.64 | 44.99 | 51.14 |
Other Operating Expenses | 5.49 | 11.18 | 18.76 | 8.38 | -1.52 | 0.57 |
Total Operating Expenses | 143.21 | 145.48 | 211.57 | 253.06 | 239.84 | 225.25 |
Operating Income | 124.49 | 104.91 | -4.69 | -91.69 | -111.47 | -180.74 |
Interest Income | 13.52 | 13.57 | 16.97 | 17 | 5.12 | 0.53 |
Interest Expense | -4.28 | -4.33 | -4.84 | -2.78 | - | - |
Total Non-Operating Income (Expense) | 9.24 | 9.24 | 12.14 | 14.22 | 5.12 | 0.53 |
Pretax Income | 133.73 | 114.16 | 7.45 | -77.47 | -106.35 | -180.21 |
Provision for Income Taxes | -164.48 | -173.05 | 1.7 | 0.55 | 1.83 | 0.76 |
Net Income | 298.21 | 287.2 | 5.75 | -78.02 | -108.18 | -180.97 |
Net Income to Common | 298.21 | 287.2 | 5.75 | -78.02 | -108.18 | -180.97 |
Net Income Growth | 648.43% | 4893.08% | - | - | - | - |
Shares Outstanding (Basic) | 133 | 134 | 143 | 143 | 142 | 129 |
Shares Outstanding (Diluted) | 138 | 139 | 146 | 143 | 142 | 129 |
Shares Change (YoY) | -5.03% | -5.13% | 2.07% | 0.93% | 9.70% | 9.20% |
EPS (Basic) | 2.26 | 2.14 | 0.04 | -0.54 | -0.76 | -1.40 |
EPS (Diluted) | 2.17 | 2.07 | 0.04 | -0.54 | -0.76 | -1.40 |
EPS Growth | 675.00% | 5075.00% | - | - | - | - |
Shares Outstanding | 130.77 | 132.32 | 140.88 | 143.83 | 142.27 | 141.6 |
Free Cash Flow | 166.64 | 135.41 | 44.11 | -34.18 | -79.82 | -158 |
Free Cash Flow Growth | 23.07% | 206.99% | - | - | - | - |
Free Cash Flow Per Share | 1.21 | 0.98 | 0.30 | -0.24 | -0.56 | -1.22 |
Gross Margin | 89.74% | 88.46% | 87.99% | 91.94% | 95.77% | 97.61% |
Operating Margin | 41.73% | 37.06% | -1.99% | -52.24% | -83.17% | -396.31% |
Profit Margin | 99.97% | 101.47% | 2.45% | -44.45% | -80.71% | -396.81% |
FCF Margin | 55.87% | 47.84% | 18.76% | -19.47% | -59.55% | -346.44% |
EBITDA | 143.9 | 124.36 | 14.76 | -80.04 | -108.76 | -177.97 |
EBITDA Margin | 48.24% | 43.94% | 6.28% | -45.61% | -81.15% | -390.25% |
EBIT | 124.49 | 104.91 | -4.69 | -91.69 | -111.47 | -180.74 |
EBIT Margin | 41.73% | 37.06% | -1.99% | -52.24% | -83.17% | -396.31% |
Effective Tax Rate | -122.99% | -151.58% | 22.77% | -0.71% | -1.72% | -0.42% |